Drug to help diabetics during Ramadan
Diabetic Muslims can now fast during Ramadan without falling ill. Three doctors from Bangladesh, India and Pakistan have jointly identified the right drug that will allow diabetic Muslims to fast without risking complications like Hypoglycemia and Ketoacidosis.
bdnews24.com News Service
bdnews24.com
Published :
05 Oct 2005, 06:00 PM
Updated :
18 Aug 2022, 12:06 PM
Dhaka, Oct 6 (BDNEWS)- Diabetic Muslims can now fast during Ramadan without falling ill. Three doctors from Bangladesh, India and Pakistan have jointly identified the right drug that will allow diabetic Muslims to fast without risking complications like Hypoglycemia and Ketoacidosis.
Dr Hajera Mahtab, director of clinical research at internationally reputed BIRDEM Hospital in Dhaka, Dr Abdul Zargar, head of the department of endocrinology at S K Institute of Medical Sciences in Srinagar and Dr Abdul Basit, head of Bagai Institute of Diabetology in Karachi have identified medical formulations of Sulphonylureas (the first line drugs used for Type 2 diabetes) that can become drug of choice during Ramadan.
According to the doctors, drugs like Repaglinide and Natiglinide, short acting drugs in the Sulphonylureas family, should be taken twice a day.
Although Islam exempts sick people from fasting, over 80 per cent of diabetic Muslims in India and most of the Muslims in Bangladesh fast during Ramadan.
"It is normal for patients during Ramadan to take two to three meals during a short span of 10-16 hours. The first meal is taken immediately after sunset, the second about three hours later and the third at dead of night to start fasting", said Dr Hajera Mahtab.
Therefore, long duration drugs will not work, causing Hypoglycemia and Ketoacidosis. Repaglinide and Natiglinide are short duration drugs that will help bring down the blood sugar immediately," the expert added.
The recent surveys have suggested that nearly 64 per cent Muslim diabetic patients change their drug intake pattern during Ramadan. Of these, 35 per cent stop treatment, 8 per cent change their dosage schedule and 18 per cent take their daily dose in a single dose.
Another large epidemiological survey found that 25 per cent of diabetic patients change their oral drug dose while fasting. "These changes in meal timings lead to an alteration in physical activity, food, fluid and sugar intake, weight and sleep duration in half the patients."
There are also alterations in serum lipids, plasma insulin, and C peptide and insulin resistance. This leads to significantly greater occurrence of cases of Hypoglycemia and Ketoacidosis during the one-month fasting associated directly with change in oral drug intake and change in food and sugar consumption pattern.
Our studies have shown that short-term Sulphonylureas with two-hour duration significantly reduce plasma glucose throughout 24 hours," Dr Hajera added.
BDNEWS/1708 hrs